116 related articles for article (PubMed ID: 29751565)
1. Upregulation of the Chemokine Receptor CCR2B in Epstein‒Barr Virus-Positive Burkitt Lymphoma Cell Lines with the Latency III Program.
Kozireva S; Rudevica Z; Baryshev M; Leonciks A; Kashuba E; Kholodnyuk I
Viruses; 2018 May; 10(5):. PubMed ID: 29751565
[TBL] [Abstract][Full Text] [Related]
2. Expression of the chemokine receptors CCR1 and CCR2B is up-regulated in peripheral blood B cells upon EBV infection and in established lymphoblastoid cell lines.
Kholodnyuk I; Rudevica Z; Leonciks A; Ehlin-Henriksson B; Kashuba E
Virology; 2017 Dec; 512():1-7. PubMed ID: 28892735
[TBL] [Abstract][Full Text] [Related]
3. Three restricted forms of Epstein-Barr virus latency counteracting apoptosis in c-myc-expressing Burkitt lymphoma cells.
Kelly GL; Milner AE; Baldwin GS; Bell AI; Rickinson AB
Proc Natl Acad Sci U S A; 2006 Oct; 103(40):14935-40. PubMed ID: 17001014
[TBL] [Abstract][Full Text] [Related]
4. Epstein-Barr virus-associated Burkitt lymphomagenesis selects for downregulation of the nuclear antigen EBNA2.
Kelly G; Bell A; Rickinson A
Nat Med; 2002 Oct; 8(10):1098-104. PubMed ID: 12219084
[TBL] [Abstract][Full Text] [Related]
5. Different patterns of Epstein-Barr virus latency in endemic Burkitt lymphoma (BL) lead to distinct variants within the BL-associated gene expression signature.
Kelly GL; Stylianou J; Rasaiyaah J; Wei W; Thomas W; Croom-Carter D; Kohler C; Spang R; Woodman C; Kellam P; Rickinson AB; Bell AI
J Virol; 2013 Mar; 87(5):2882-94. PubMed ID: 23269792
[TBL] [Abstract][Full Text] [Related]
6. Resveratrol inhibits proliferation and survival of Epstein Barr virus-infected Burkitt's lymphoma cells depending on viral latency program.
De Leo A; Arena G; Stecca C; Raciti M; Mattia E
Mol Cancer Res; 2011 Oct; 9(10):1346-55. PubMed ID: 21856773
[TBL] [Abstract][Full Text] [Related]
7. Restoration of endogenous antigen processing in Burkitt's lymphoma cells by Epstein-Barr virus latent membrane protein-1: coordinate up-regulation of peptide transporters and HLA-class I antigen expression.
Rowe M; Khanna R; Jacob CA; Argaet V; Kelly A; Powis S; Belich M; Croom-Carter D; Lee S; Burrows SR
Eur J Immunol; 1995 May; 25(5):1374-84. PubMed ID: 7774641
[TBL] [Abstract][Full Text] [Related]
8. Elevated expression of c-myc in lymphoblastoid cells does not support an Epstein-Barr virus latency III-to-I switch.
Pajic A; Polack A; Staege MS; Spitkovsky D; Baier B; Bornkamm GW; Laux G
J Gen Virol; 2001 Dec; 82(Pt 12):3051-3055. PubMed ID: 11714983
[TBL] [Abstract][Full Text] [Related]
9. Enhanced susceptibility of B lymphoma cells to measles virus by Epstein-Barr virus type III latency that upregulates CD150/signaling lymphocytic activation molecule.
Takeda S; Kanbayashi D; Kurata T; Yoshiyama H; Komano J
Cancer Sci; 2014 Feb; 105(2):211-8. PubMed ID: 24238277
[TBL] [Abstract][Full Text] [Related]
10. Differential regulation of Epstein-Barr virus (EBV) latent gene expression in Burkitt lymphoma cells infected with a recombinant EBV strain.
Trivedi P; Spinsanti P; Cuomo L; Volpe M; Takada K; Frati L; Faggioni A
J Virol; 2001 May; 75(10):4929-35. PubMed ID: 11312367
[TBL] [Abstract][Full Text] [Related]
11. Proteoglycan expression correlates with the phenotype of malignant and non-malignant EBV-positive B-cell lines.
Tsidulko AY; Matskova L; Astakhova LA; Ernberg I; Grigorieva EV
Oncotarget; 2015 Dec; 6(41):43529-39. PubMed ID: 26527314
[TBL] [Abstract][Full Text] [Related]
12. Cytokine signatures of transformed B cells with distinct Epstein-Barr virus latencies as a potential diagnostic tool for B cell lymphoma.
Miyauchi K; Urano E; Yoshiyama H; Komano J
Cancer Sci; 2011 Jun; 102(6):1236-41. PubMed ID: 21392167
[TBL] [Abstract][Full Text] [Related]
13. Interaction of Epstein-Barr virus (EBV) with human B-lymphocytes.
Klein G; Klein E; Kashuba E
Biochem Biophys Res Commun; 2010 May; 396(1):67-73. PubMed ID: 20494113
[TBL] [Abstract][Full Text] [Related]
14. Expression of the Chemokine Receptor CCR1 in Burkitt Lymphoma Cell Lines Is Linked to the CD10-Negative Cell Phenotype and Co-Expression of the EBV Latent Genes EBNA2, LMP1, and LMP2.
Zvejniece L; Kozireva S; Rudevica Z; Leonciks A; Ehlin-Henriksson B; Kashuba E; Kholodnyuk I
Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35408790
[TBL] [Abstract][Full Text] [Related]
15. Dominant-negative derivative of EBNA1 represses EBNA1-mediated transforming gene expression during the acute phase of Epstein-Barr virus infection independent of rapid loss of viral genome.
Kariya Y; Hamatake M; Urano E; Yoshiyama H; Shimizu N; Komano J
Cancer Sci; 2010 Apr; 101(4):876-81. PubMed ID: 20132216
[TBL] [Abstract][Full Text] [Related]
16. Upregulation of Epstein-Barr virus-encoded latent membrane protein by human herpesvirus 6 superinfection of EBV-carrying Burkitt lymphoma cells.
Cuomo L; Trivedi P; de Grazia U; Calogero A; D'Onofrio M; Yang W; Frati L; Faggioni A; Rymo L; Ragona G
J Med Virol; 1998 Jul; 55(3):219-26. PubMed ID: 9624610
[TBL] [Abstract][Full Text] [Related]
17. Combination of SAHA and bortezomib up-regulates CDKN2A and CDKN1A and induces apoptosis of Epstein-Barr virus-positive Wp-restricted Burkitt lymphoma and lymphoblastoid cell lines.
Hui KF; Leung YY; Yeung PL; Middeldorp JM; Chiang AK
Br J Haematol; 2014 Dec; 167(5):639-50. PubMed ID: 25155625
[TBL] [Abstract][Full Text] [Related]
18. Epstein-Barr virus nuclear antigen 2 induces interleukin-18 receptor expression in B cells.
Pagès F; Galon J; Karaschuk G; Dudziak D; Camus M; Lazar V; Camilleri-Broët S; Lagorce-Pagès C; Lebel-Binay S; Laux G; Fridman WH; Henglein B
Blood; 2005 Feb; 105(4):1632-9. PubMed ID: 15498855
[TBL] [Abstract][Full Text] [Related]
19. Simultaneous detection of the two main proliferation driving EBV encoded proteins, EBNA-2 and LMP-1 in single B cells.
Rasul AE; Nagy N; Sohlberg E; Ádori M; Claesson HE; Klein G; Klein E
J Immunol Methods; 2012 Nov; 385(1-2):60-70. PubMed ID: 22921685
[TBL] [Abstract][Full Text] [Related]
20. SH2D1A expression in Burkitt lymphoma cells is restricted to EBV positive group I lines and is downregulated in parallel with immunoblastic transformation.
Nagy N; Maeda A; Bandobashi K; Kis LL; Nishikawa J; Trivedi P; Faggioni A; Klein G; Klein E
Int J Cancer; 2002 Aug; 100(4):433-40. PubMed ID: 12115526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
